Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Chief Commercial Officer | December 27, 2023 | December 29, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amylyx Pharmaceuticals, Inc.
Report date December 27, 2023 · Filed December 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 276,108 |
Reported balance
After 2023-12-27 transaction · row 1
1 source rowRow 1 · 2023-12-27 · Exercise / conversion · Acquired 25,000 · Balance 276,108 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2029-05-13 | Direct | 44,577 |
Reported balance
After 2023-12-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-27 · Exercise / conversion · Disposed 25,000 · Balance 44,577 F1: The shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2023 Filed Dec 29, 2023 16:07 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000950170-23-073837 · ownership.xml · derivative · entry 2 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,577 Underlying: Common Stock · 25,000 shares Expires 2029-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 16:07 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionCommon Stock | 25,000 | $0.37 | $9,250.00 |
DisclosureSEC source: 0000950170-23-073837 · ownership.xml · nonDerivative · entry 1 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 16:20 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000950170-23-033003 · ownership.xml · derivative · entry 2 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,577 Underlying: Common Stock · 20,000 shares Expires 2029-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of the date of this filing, 67,156 shares subject to the option are vested and exercisable. 2,421 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 16:20 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionCommon Stock | 20,000 | $0.37 | $7,400.00 |
DisclosureSEC source: 0000950170-23-033003 · ownership.xml · nonDerivative · entry 1 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2023 Filed May 24, 2023 16:38 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-023942 · ownership.xml · nonDerivative · entry 1 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,108 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:27 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009180 · doc4.xml · derivative · entry 2 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-03-16 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:27 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009180 · doc4.xml · nonDerivative · entry 1 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,688 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 19:19 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 743 | $36.79 | $27,334.08 |
DisclosureSEC source: 0000899243-23-001520 · doc4.xml · nonDerivative · entry 2 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,355 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 19:19 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 1,660 | $36.08 | $59,890.97 |
DisclosureSEC source: 0000899243-23-001520 · doc4.xml · nonDerivative · entry 1 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,098 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 20:30 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 127,500 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001516 · doc4.xml · derivative · entry 3 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 127,500 shares Expires 2032-01-06 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 20:30 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 6,842 | $19.00 | $129,998.00 |
DisclosureSEC source: 0000899243-22-001516 · doc4.xml · nonDerivative · entry 2 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,758 Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 20:30 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantCommon Stock | 28,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001516 · doc4.xml · nonDerivative · entry 1 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,916 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first anniversary of the date of the grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.